Developer docs
API playgroundTry for free, no card

Search company profiles

Endpoint Health

Full company profile

uuid0000k2z

Namestring
Endpoint Health
Legal namestring
Endpoint Health, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Endpoint Health is a precision immunology company founded in 2018 and headquartered in Palo Alto, California. The company is developing an integrated platform that combines therapeutics, diagnostic tests, and artificial intelligence to deliver targeted treatments for immune-mediated diseases, with an initial clinical focus on sepsis. Its lead asset is the Antithrombin III program, a therapeutic candidate advancing into Phase II clinical trials, with planned regulatory submissions to the FDA.

The company was co-founded by Jason Springs (CEO), Leonardo Maestri Teixeira (COO), and Diego Rey (CSO), and is venture-backed. To date, Endpoint Health has raised approximately $64 million across funding rounds, including a $52 million Series A in June 2022 led by Mayfield Fund with participation from AME Cloud Ventures, Humboldt Fund, the Global Health Investment Fund, Y Combinator alumni investors, and several other institutional investors. The company went through the Y Combinator accelerator in 2019.

Endpoint Health is a pre-commercial, clinical-stage biotechnology company. It has no approved products, no disclosed revenue, and no commercial customers. Its business model is built around developing and ultimately commercializing precision immunology therapeutics, with an integrated companion diagnostic and AI-based patient stratification component. Revenue generation would be dependent on successful clinical trial outcomes, regulatory approval, and future commercialization of its therapeutic pipeline.

Short descriptiontext

Endpoint Health is a clinical-stage precision immunology company developing an integrated therapeutics, diagnostic, and AI platform to treat immune-mediated diseases, with its lead Antithrombin III program advancing to Phase II trials for sepsis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision immunology therapeutics, sepsis treatment development, clinical-stage biopharmaceutical, immune-mediated disease therapies, diagnostics AI platform
Industry2 codes
PRIMARYHLAGAEAH
Imaging Core Labs & Clinical Endpoint Adjudication
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Immunology Therapeutics
Social media profiles1 record
Revenue model1 record
1Therapeutic Product Revenue
TypeOne Time License
Description

Revenue derived from developing and commercializing precision immunology therapeutics. The company is in clinical development stage with Antithrombin III program advancing to Phase II trials for sepsis treatment.

finsmes.com
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Endpoint Health is a clinical-stage therapeutics company developing precision immunology treatments for immune-mediated diseases. Its lead program is Antithrombin III, a therapeutic candidate for sepsis that is progressing to a Phase II clinical trial with planned FDA regulatory submissions. The company combines therapeutics, diagnostic tests, and artificial intelligence within a single platform to enable targeted treatment of conditions such as sepsis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Endpoint Health operates as a therapeutics company developing precision therapies for immune-mediated diseases. The company's portfolio includes the Antithrombin III Program, a therapeutic candidate for sepsis undergoing Phase II clinical development. The offerings combine therapeutics, diagnostic tests, and AI technologies to enable precision immunology approaches.

Product and service1 record
1Antithrombin III Program
CategoryPrecision Immunology Therapeutics
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche operates across diagnostics, immunology therapeutics, and AI-driven clinical decision support — a broad incumbent whose portfolio most closely mirrors Endpoint Health's stated integrated therapeutics–diagnostics–AI strategy at scale.

TypeDirect peer
Description

Cytovale markets IntelliSep, a rapid cellular biomarker diagnostic that aids early sepsis identification in the ER — a direct analog to Endpoint Health's diagnostic-test-driven approach to sepsis decision-making.

TypeEmerging player
Description

Prenosis applies AI-driven biomarker analytics to immune-mediated disease diagnostics (e.g., Sepsis ImmunoScore) — closely aligned with Endpoint Health's precision immunology platform combining diagnostics, AI, and clinical decision support.

TypeDirect peer
Description

Inflammatix develops AI/ML-based host-response diagnostics for acute infections and sepsis — directly comparable to Endpoint Health's integration of diagnostics and AI for immune-mediated disease management.

TypeBroad incumbent
Description

Regeneron is a leading immunology therapeutics developer (Dupixent, IL-4Rα franchise) with a track record of combining biologics with genetic/diagnostic patient selection — a large incumbent demonstrating the precision immunology commercial model Endpoint Health aspires to.

6Inotrem
TypeDirect peer
Description

Inotrem is a French clinical-stage biotech developing a TREM-1 inhibitor (nangibotide) for septic shock — a precision immunology approach to sepsis therapeutics that competes head-to-head with Endpoint Health's positioning.

TypeBroad incumbent
Description

Grifols markets Thrombate III (Antithrombin III) for hereditary antithrombin deficiency and has hospital-channel reach in critical care — an established competitor whose antithrombin franchise could overlap with a commercialized Endpoint Health product.

TypeBroad incumbent
Description

Takeda markets ATryn, a recombinant antithrombin product, and has deep critical-care commercial infrastructure — a broad incumbent comparable on the antithrombin therapeutic modality and ICU channel access.

9Asahi Kasei Pharma
TypeBroad incumbent
Description

Asahi Kasei markets an antithrombin III concentrate and is a major global plasma-derived therapeutics manufacturer — a broad incumbent with potential overlap in the antithrombin sepsis positioning.

TypeBroad incumbent
Description

bioMérieux (including BioFire Diagnostics) is a global leader in clinical microbiology and sepsis diagnostics — an established incumbent in the diagnostic-and-AI sepsis workflow that Endpoint Health's diagnostic components would compete against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Endpoint Health

Precision Immunology Therapeuticsendpointhealth.com

Endpoint Health is a clinical-stage precision immunology company developing an integrated therapeutics, diagnostic, and AI platform to treat immune-mediated diseases, with its lead Antithrombin III program advancing to Phase II trials for sepsis.

What Endpoint Health does

Endpoint Health is a precision immunology company founded in 2018 and headquartered in Palo Alto, California. The company is developing an integrated platform that combines therapeutics, diagnostic tests, and artificial intelligence to deliver targeted treatments for immune-mediated diseases, with an initial clinical focus on sepsis. Its lead asset is the Antithrombin III program, a therapeutic candidate advancing into Phase II clinical trials, with planned regulatory submissions to the FDA.

The company was co-founded by Jason Springs (CEO), Leonardo Maestri Teixeira (COO), and Diego Rey (CSO), and is venture-backed. To date, Endpoint Health has raised approximately $64 million across funding rounds, including a $52 million Series A in June 2022 led by Mayfield Fund with participation from AME Cloud Ventures, Humboldt Fund, the Global Health Investment Fund, Y Combinator alumni investors, and several other institutional investors. The company went through the Y Combinator accelerator in 2019.

Endpoint Health is a pre-commercial, clinical-stage biotechnology company. It has no approved products, no disclosed revenue, and no commercial customers. Its business model is built around developing and ultimately commercializing precision immunology therapeutics, with an integrated companion diagnostic and AI-based patient stratification component. Revenue generation would be dependent on successful clinical trial outcomes, regulatory approval, and future commercialization of its therapeutic pipeline.

Endpoint Health firmographics

Firmographics
Name
Endpoint Health
Legal name
Endpoint Health, Inc.
Website
https://endpointhealth.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Endpoint Health is a clinical-stage precision immunology company developing an integrated therapeutics, diagnostic, and AI platform to treat immune-mediated diseases, with its lead Antithrombin III program advancing to Phase II trials for sepsis.
Ownership category
akta.pro rank

Endpoint Health industry classification

Industry
Product category
Precision Immunology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medical and Diagnostic Laboratories (62151)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAEAH
Imaging Core Labs & Clinical Endpoint Adjudication
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Precision immunology therapeutics
  • Sepsis treatment development
  • Clinical-stage biopharmaceutical
  • Immune-mediated disease therapies
  • Diagnostics AI platform

Where Endpoint Health is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Endpoint Health business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Therapeutic Product Revenue: Revenue derived from developing and commercializing precision immunology therapeutics. The company is in clinical development stage with Antithrombin III program advancing to Phase II trials for sepsis treatment.

Endpoint Health product offering

Product offering

Core offering

Endpoint Health is a clinical-stage therapeutics company developing precision immunology treatments for immune-mediated diseases. Its lead program is Antithrombin III, a therapeutic candidate for sepsis that is progressing to a Phase II clinical trial with planned FDA regulatory submissions. The company combines therapeutics, diagnostic tests, and artificial intelligence within a single platform to enable targeted treatment of conditions such as sepsis.

Product overview

Endpoint Health operates as a therapeutics company developing precision therapies for immune-mediated diseases. The company's portfolio includes the Antithrombin III Program, a therapeutic candidate for sepsis undergoing Phase II clinical development. The offerings combine therapeutics, diagnostic tests, and AI technologies to enable precision immunology approaches.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antithrombin III Program

Companies that use Endpoint Health

Customer profile

Segments1 record

Ideal customer profiles1 record

Endpoint Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Endpoint Health partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Endpoint Health competitors and assessment

Company assessment

Broad incumbents

  • Roche: Roche operates across diagnostics, immunology therapeutics, and AI-driven clinical decision support — a broad incumbent whose portfolio most closely mirrors Endpoint Health's stated integrated therapeutics–diagnostics–AI strategy at scale.
  • Regeneron Pharmaceuticals: Regeneron is a leading immunology therapeutics developer (Dupixent, IL-4Rα franchise) with a track record of combining biologics with genetic/diagnostic patient selection — a large incumbent demonstrating the precision immunology commercial model Endpoint Health aspires to.
  • Grifols: Grifols markets Thrombate III (Antithrombin III) for hereditary antithrombin deficiency and has hospital-channel reach in critical care — an established competitor whose antithrombin franchise could overlap with a commercialized Endpoint Health product.
  • Takeda Pharmaceutical: Takeda markets ATryn, a recombinant antithrombin product, and has deep critical-care commercial infrastructure — a broad incumbent comparable on the antithrombin therapeutic modality and ICU channel access.
  • Asahi Kasei Pharma: Asahi Kasei markets an antithrombin III concentrate and is a major global plasma-derived therapeutics manufacturer — a broad incumbent with potential overlap in the antithrombin sepsis positioning.
  • bioMérieux: bioMérieux (including BioFire Diagnostics) is a global leader in clinical microbiology and sepsis diagnostics — an established incumbent in the diagnostic-and-AI sepsis workflow that Endpoint Health's diagnostic components would compete against.

Direct peers

  • Cytovale: Cytovale markets IntelliSep, a rapid cellular biomarker diagnostic that aids early sepsis identification in the ER — a direct analog to Endpoint Health's diagnostic-test-driven approach to sepsis decision-making.
  • Inflammatix: Inflammatix develops AI/ML-based host-response diagnostics for acute infections and sepsis — directly comparable to Endpoint Health's integration of diagnostics and AI for immune-mediated disease management.
  • Inotrem: Inotrem is a French clinical-stage biotech developing a TREM-1 inhibitor (nangibotide) for septic shock — a precision immunology approach to sepsis therapeutics that competes head-to-head with Endpoint Health's positioning.

Emerging players

  • Prenosis: Prenosis applies AI-driven biomarker analytics to immune-mediated disease diagnostics (e.g., Sepsis ImmunoScore) — closely aligned with Endpoint Health's precision immunology platform combining diagnostics, AI, and clinical decision support.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Endpoint Health social profiles

Digital presence

Endpoint Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Endpoint Health leadership team

Management profile

Number of profiles

Profiles3 records

Endpoint Health funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Endpoint Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endpoint Health

What does Endpoint Health do?

Endpoint Health is a clinical-stage therapeutics company developing precision immunology treatments for immune-mediated diseases. Its lead program is Antithrombin III, a therapeutic candidate for sepsis that is progressing to a Phase II clinical trial with planned FDA regulatory submissions. The company combines therapeutics, diagnostic tests, and artificial intelligence within a single platform to enable targeted treatment of conditions such as sepsis.

Is Endpoint Health a public or private company?

Endpoint Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was Endpoint Health founded?

Endpoint Health was founded in 2018. It employs 1 to 10 people.

Where is Endpoint Health based?

Endpoint Health is headquartered in Palo Alto, United States, in the North America region.

How does Endpoint Health make money?

One revenue line is on record: therapeutic Product Revenue.

Who are Endpoint Health's main competitors?

Broad incumbents on record are Roche, Regeneron Pharmaceuticals, Grifols, Takeda Pharmaceutical, Asahi Kasei Pharma and bioMérieux. Direct peers are Cytovale, Inflammatix and Inotrem. Prenosis is listed as an emerging player.

Does Endpoint Health have an API?

No public API is recorded for Endpoint Health.

What industry is Endpoint Health in?

Endpoint Health's product category is Precision Immunology Therapeutics. Its primary akta.pro industry code is HLAGAEAH, Imaging Core Labs & Clinical Endpoint Adjudication, with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
STATUp and down the ladder: The latest comings and goingsEndpoint Health has appointed Ransi Somaratne as its new chief medical officer, following his previous roles at Spring Discovery and Epirium. The article highlights Somaratne's personal interests in studying various languages during his spare time. This announcement is part of a regular feature highlighting executive changes.BioSpaceEndpoint Health Appoints Ransi Somaratne, M.D. as Chief Medical OfficerEndpoint Health appointed Ransi Somaratne, M.D., as Chief Medical Officer, effective immediately. He will lead clinical strategy and drug development across its precision immunology pipeline. Somaratne previously served as CMO at Spring Discovery and held leadership roles at BioMarin and Amgen.Bio-itworldFollow the Money: Drug Discovery Robotics Lab, Clinical Sequencing Platform, MoreMultiple life sciences and healthcare companies, including Insilico Medicine, Endpoint Health, and Epic Sciences, secured significant funding rounds ranging from $2.9 million to $60 million to advance drug discovery, diagnostics, and AI-driven platforms. Biospring Partners also closed its debut fund with over $245 million in capital commitments to invest in B2B life sciences technology firms. These investments are directed toward expanding pipelines, launching robotic labs, and scaling commercial operations for various therapeutic and diagnostic technologies.BioSpaceEndpoint Health Raises $52 Million in Financing to Expand and Progress Precision Immunology PipelineEndpoint Health closed $52 million in equity and debt financing, with proceeds to expand its precision immunology pipeline. The company will advance its Antithrombin III therapy to a Phase II trial for sepsis and expects to submit an IND application later this year.VC News DailyEndpoint Health Raises $52MEndpoint Health announced the closing of a $52 million Series A financing round combining equity and debt. The investment was led by major institutional investors including Mayfield, Humboldt Fund, AME Cloud Ventures, Boom Capital, Alix Ventures, Yaya Capital, Wireframe Ventures, The Venture Collective, HCX Ventures, and Global Health Investment Corporation.FinSMEsEndpoint Health Raises $52M in FinancingEndpoint Health closed a $52 million Series A equity and debt financing round led by major institutional investors including Mayfield and AME Cloud Ventures. The company intends to use the proceeds to advance its precision therapy Antithrombin III to Phase II clinical trials for sepsis and expand its therapeutic pipeline. This funding follows a recent global collaboration agreement with Grifols to develop and commercialize the drug.Venture Capital Access OnlineEndpoint Health Raises $52 Million in Financing to Expand and Progress Precision Immunology PipelineEndpoint Health closed a $52 million Series A financing round led by major institutional investors to expand its precision immunology pipeline. The company plans to use the proceeds to advance its first therapy, Antithrombin III, into Phase II clinical trials for sepsis and submit an Investigational New Drug application later this year.PR NewswireGrifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for SepsisGrifols signed a global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III (AT-III) therapy for treating Sepsis, with Grifols providing up to USD 25 million in funding and serving as the exclusive supplier of the plasma protein. Endpoint Health will manage clinical development, regulatory approval, and commercialization, receiving exclusive global rights except in China, while Grifols receives royalties on future net sales. Upon FDA approval of the Phase II clinical trial IND application expected later this year, the companies plan to invest in expanding AT-III production capacity at Grifols manufacturing sites.TechCrunchSaving Lives with Precision BiologyIllumina, Adaptive Bio, Mission Bio, and Endpoint are prominent companies in the fields of next-generation sequencing, immune-driven medicine, single cell multi-omics, and precision therapies, respectively. These organizations are utilizing biological breakthroughs to address various medical challenges, including inflammatory illnesses and sepsis. The discussion focuses on the translation of innovations from research to practical applications in healthcare.GlobeNewswirePress news Biocartis Group NV: Biocartis Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical IllnessBiocartis announced a partnership with Endpoint Health to develop a companion diagnostic test on its Idylla platform for critically ill patients. The test will be developed and registered in interventional trials, with development starting in Q4 2020. The partnership aims to guide targeted therapies for conditions like sepsis and ARDS.